| 31st Mar 2025 4:39 pm |
GNW |
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility |
| 5th Mar 2025 5:59 am |
GNW |
Sandoz reports strong FY 2024 results and Q4 2024 sales |
| 24th Feb 2025 6:00 am |
GNW |
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] |
| 3rd Feb 2025 6:00 am |
GNW |
Francisco Ballester to retire; Peter Stenico appointed President Region International |
| 14th Jan 2025 6:00 am |
GNW |
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference |
| 17th Dec 2024 6:00 am |
GNW |
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation |
| 15th Nov 2024 6:00 am |
GNW |
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio |
| 30th Oct 2024 6:00 am |
GNW |
Sandoz reports third-quarter and nine-month 2024 sales |
| 12th Aug 2024 6:00 am |
GNW |
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position |
| 8th Aug 2024 6:00 am |
GNW |
Sandoz reports second-quarter sales and half-year 2024 results |
| 25th Jul 2024 6:00 am |
GNW |
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases |
| 1st Jul 2024 6:00 am |
GNW |
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US |
| 22nd May 2024 6:00 am |
GNW |
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe |
| 30th Apr 2024 11:25 am |
GNW |
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG |
| 30th Apr 2024 6:00 am |
GNW |
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars |
| 22nd Apr 2024 6:00 am |
GNW |
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering |
| 21st Mar 2024 1:00 pm |
GNW |
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines |
| 13th Mar 2024 6:00 am |
GNW |
Sandoz reports fourth quarter 2023 sales and full-year 2023 results |
| 5th Mar 2024 6:24 pm |
GNW |
Sandoz receives FDA approval for first and only denosumab biosimilars |
| 5th Mar 2024 6:00 am |
GNW |
Sandoz announces nominations to the Board of Directors and leadership change |
| 4th Mar 2024 6:00 am |
GNW |
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market |
| 29th Feb 2024 6:00 am |
GNW |
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs |
| 1st Feb 2024 6:15 am |
GNW |
Sandoz announces changes in the Board of Directors |
| 31st Jan 2024 6:00 am |
GNW |
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany |
| 22nd Jan 2024 6:00 am |
GNW |
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market |
| 21st Nov 2023 6:00 am |
GNW |
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care |
| 10th Nov 2023 1:02 pm |
GNW |
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany |
| 8th Nov 2023 5:46 pm |
GNW |
Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds |
| 26th Oct 2023 4:45 pm |
GNW |
Sandoz successfully issues CHF 750 million in inaugural bonds |
| 24th Oct 2023 6:15 am |
GNW |
Sandoz reports year-to-date sales for the first nine months of 2023 |
